Free Trial

Catalyst Pharmaceuticals (CPRX) SEC Filings & 10K Form

Catalyst Pharmaceuticals logo
$20.95 -0.67 (-3.10%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$21.01 +0.06 (+0.29%)
As of 07:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Catalyst Pharmaceuticals SEC Filings

DateFilerForm TypeView
06/06/2025
2:42 PM
Catalyst Pharmaceuticals (Subject)
MCENANY PATRICK J (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/02/2025
1:44 PM
Catalyst Pharmaceuticals (Subject)
O'Keeffe Charles B (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/14/2025
9:45 AM
Catalyst Pharmaceuticals (Subject)
INGENITO GARY (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/13/2025
10:14 AM
Catalyst Pharmaceuticals (Subject)
INGENITO GARY (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/28/2025
11:32 AM
BlackRock, Inc. (Filed by)
Catalyst Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
04/14/2025
4:19 PM
Catalyst Pharmaceuticals (Filer)
Form ARS
04/09/2025
7:55 AM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/07/2025
4:00 PM
Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2025
3:09 PM
Catalyst Pharmaceuticals (Subject)
INGENITO GARY (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
3:21 PM
Catalyst Pharmaceuticals (Subject)
Elsbernd Brian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
9:21 AM
Catalyst Pharmaceuticals (Subject)
Del Carmen Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/28/2025
4:40 PM
Catalyst Pharmaceuticals (Issuer)
Russo Gregg (Reporting)
Form 3/A
02/26/2025
3:37 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/26/2025
3:05 PM
Catalyst Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/13/2025
7:57 AM
Catalyst Pharmaceuticals (Subject)
Flynn James E (Filed by)
Form SCHEDULE 13G/A
01/24/2025
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/21/2025
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
5:07 AM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
Harper Molly (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
Sundaram Preethi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
Del Carmen Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
DENKHAUS DONALD A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
Daly Richard J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
O'Keeffe Charles B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2024
3:30 PM
Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2024
4:24 PM
Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Del Carmen Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Sundaram Preethi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
DENKHAUS DONALD A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
O'Keeffe Charles B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Harper Molly (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Thompson Tamar (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/10/2024
11:55 AM
Catalyst Pharmaceuticals (Subject)
Miller Steve (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
3..2..1.. AI 2.0 ignition (don’t sleep on this) (Ad)

I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.

Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave.
11/29/2024
7:08 PM
Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/29/2024
7:09 PM
Catalyst Pharmaceuticals (Issuer)
Harper Molly (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/29/2024
7:09 PM
Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
1:42 PM
Catalyst Pharmaceuticals (Subject)
INGENITO GARY (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/27/2024
8:42 AM
Catalyst Pharmaceuticals (Subject)
Harper Molly (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/26/2024
11:37 AM
Catalyst Pharmaceuticals (Subject)
Elsbernd Brian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/25/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Thompson Tamar (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Daly Richard J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Harper Molly (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
O'Keeffe Charles B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
Kalb Michael Wayne (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
DENKHAUS DONALD A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
Sundaram Preethi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
Del Carmen Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/22/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2024
4:11 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2024
1:57 PM
Catalyst Pharmaceuticals (Subject)
MCENANY PATRICK J (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/15/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2024
8:55 AM
Catalyst Pharmaceuticals (Subject)
Flynn James E (Filed by)
Form SC 13G/A
11/13/2024
4:44 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2024
9:52 AM
Catalyst Pharmaceuticals (Subject)
MCENANY PATRICK J (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/06/2024
4:10 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2024
3:08 PM
Catalyst Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/18/2024
2:31 PM
BlackRock, Inc. (Filed by)
Catalyst Pharmaceuticals (Subject)
Form SC 13G/A
10/17/2024
11:14 AM
Catalyst Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
09/26/2024
7:42 AM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/23/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2024
1:21 PM
Catalyst Pharmaceuticals (Subject)
Tierney David S (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/20/2024
3:42 PM
Catalyst Pharmaceuticals (Subject)
Miller Steve (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/19/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/09/2024
1:53 PM
Catalyst Pharmaceuticals (Subject)
INGENITO GARY (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/09/2024
10:24 AM
Catalyst Pharmaceuticals (Subject)
Del Carmen Jeffrey (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
3:32 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/26/2024
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:CPRX) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners